[go: up one dir, main page]

SE402592B - Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner - Google Patents

Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner

Info

Publication number
SE402592B
SE402592B SE7304464A SE7304464A SE402592B SE 402592 B SE402592 B SE 402592B SE 7304464 A SE7304464 A SE 7304464A SE 7304464 A SE7304464 A SE 7304464A SE 402592 B SE402592 B SE 402592B
Authority
SE
Sweden
Prior art keywords
pyrazolo
pyridines
acyl
alkyl
procedure
Prior art date
Application number
SE7304464A
Other languages
English (en)
Inventor
T Irikura
M Hayashi
K Koshirae
Y Kudo
J Hatayama
E Hetsugi
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of SE402592B publication Critical patent/SE402592B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7304464A 1972-03-30 1973-03-29 Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner SE402592B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (sv) 1972-03-30 1972-03-30

Publications (1)

Publication Number Publication Date
SE402592B true SE402592B (sv) 1978-07-10

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7304464A SE402592B (sv) 1972-03-30 1973-03-29 Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner

Country Status (12)

Country Link
US (1) US3850941A (sv)
JP (1) JPS5229318B2 (sv)
AR (1) AR197709A1 (sv)
BE (1) BE797554A (sv)
BR (1) BR7302268D0 (sv)
CA (1) CA989843A (sv)
DE (1) DE2315801C3 (sv)
ES (1) ES413188A1 (sv)
FR (1) FR2182914B1 (sv)
GB (1) GB1378375A (sv)
HU (1) HU167305B (sv)
SE (1) SE402592B (sv)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (sv) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
OA12905A (en) 2002-08-19 2006-10-13 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
EA009646B1 (ru) 2003-05-30 2008-02-28 Рэнбакси Лабораториз Лтд. Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005051293A2 (en) 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1948599A1 (en) 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RU2008152776A (ru) * 2006-06-06 2010-07-20 Эвиджен Инк. (Us) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080181876A1 (en) 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
WO2009008748A1 (en) * 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
MX2010001650A (es) * 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
JP5263548B2 (ja) * 2007-08-15 2013-08-14 杏林製薬株式会社 イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
WO2010005520A2 (en) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
RU2618628C1 (ru) 2013-04-17 2017-05-05 Пфайзер Инк. Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
CA3125765A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Also Published As

Publication number Publication date
AR197709A1 (es) 1974-04-30
JPS4897898A (sv) 1973-12-13
DE2315801A1 (de) 1973-10-11
BR7302268D0 (pt) 1974-08-29
GB1378375A (en) 1974-12-27
CA989843A (en) 1976-05-25
AU5376173A (en) 1974-09-26
HU167305B (sv) 1975-09-27
JPS5229318B2 (sv) 1977-08-01
DE2315801B2 (de) 1978-06-22
FR2182914B1 (sv) 1976-05-14
FR2182914A1 (sv) 1973-12-14
US3850941A (en) 1974-11-26
ES413188A1 (es) 1976-01-16
BE797554A (fr) 1973-07-16
DE2315801C3 (de) 1979-02-22

Similar Documents

Publication Publication Date Title
SE402592B (sv) Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner
SE432767B (sv) Forfarande for framstellning av oxazolo-(5,4-b)-pyridiner
SE407579B (sv) Forfarande for framstellning av n-fosfonometylglycin
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
SE395149B (sv) Forfarande for framstellning av dibenso-tiepinylpiperazinderivat
SE381047B (sv) Forfarande for framstellning av 3-substituerade 1,2-bensisoxazolderivat
SE401676B (sv) Forfarande for framstellning av dibensofuranderivat
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
SE383151B (sv) Forfarande for framstellning av 1-hydroxi-2-pyridoner
RO79057A (ro) Procedeu pentru prepararea unor imidazoli-(4,5-b)-piridine
AR192347A1 (es) Procedimiento para la preparacion de 3-amino-imidazo(1,5-a)piridinas
SE402009B (sv) Forfarande for framstellning av 9-desoxi-prosta-5,9,(10),13-triensyraderivat
SE400768B (sv) Forfarande for framstellning av 2-fenyl-6-sulfamoyl-7-klor-1,2,3,4-tetrahydro-4-kinazolinon
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
SE393111B (sv) Forfarande for framstellning av d-2-halogen-6-metyl-8-substituerad - ergolin
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE415355B (sv) Forfarande for framstellning av fosfonotioureider
SE393808B (sv) Forfarande for framstellning av isomaltit
FI52735C (sv) Förfarande för framställning av nya pregnadien-21-syraderivat.
SE399557B (sv) Forfarande for framstellning av tiantren-, tioxanten- och fenoxatiinderivat
SE400086B (sv) Forfarande for framstellning av acylerade n(6)- aralkyl-adenosin-derivat
SE391717B (sv) Forfarande for framstellning av 4-aryl-5-aminoalkyl-4-oxazolin-2-oner
SE380804B (sv) Anologiforfarande for framstellning av s-triazolo (1,5-a) (1,4)
BG20583A3 (bg) Метод за получаване на 2,6-диамино-дихидропиридини
SE389862B (sv) Forfarande for framstellning av alfa-6-deoxitetracykliner